[6-hydroxy-2-(4-methanesulfonyl-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone hydrochloride | 648905-82-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: [6-hydroxy-2-(4-methanesulfonyl-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone hydrochloride
• 英文别名: [6-hydroxy-2-(4-methylsulfonylphenyl)naphthalen-1-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone;hydrochloride
• CAS: 648905-82-2
• 化学式: C₃₁H₃₁NO₅S*ClH
• 分子量: 566.118
• InChiKey: YXJABUBLNICNQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.13
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  92.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  [6-hydroxy-2-(4-methanesulfonyl-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone 在 盐酸 作用下， 以 水 、 乙腈 为溶剂， 以68%的产率得到[6-hydroxy-2-(4-methanesulfonyl-phenyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone hydrochloride
  参考文献：
  名称：

  [EN] SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP
  [FR] MODULATEURS SELECTIFS DES RECEPTEURS OESTROGENIQUES CONTENANT UN GROUPE PHENYLSULFONYLE

  摘要：

  本发明涉及式I的选择性雌激素受体调节剂或其药用酸盐加合物；例如，用于治疗子宫内膜异位症和/或子宫平滑肌瘤。

  公开号：

  WO2004009086A1

文献信息

• FLUORINE-SUBSTITUTED AMPHETAMINES AND AMPHETAMINE DERIVATIVES AND USE THEREOF
  申请人：Nagel Ulrich

  公开号：US20100179221A1

  公开（公告）日：2010-07-15

  A fluorine-substituted amphetamine or amphetamine derivative with the formula (I): where at least one of the residues R1 or R2 is different from H and Ph is a phenyl ring, which is substituted with fluorine in at least one position or the residues R1 and R2 independently of one another are H or are different from H and Ph is a phenyl ring, which is substituted with fluorine in at least three positions or the residues R1 and R2 independently of one another are H or are different from H and Ph is a phenyl ring, which is substituted with fluorine in at least one position and has a substituent different from H in at least one other position.

  一种氟代苯丙胺或苯丙胺衍生物，化学式为（I）：其中残基R1或R2中至少有一个不同于H，Ph为苯环，至少在一个位置上用氟取代，或残基R1和R2彼此独立地是H或不同于H，Ph为苯环，在至少三个位置上用氟取代，或残基R1和R2彼此独立地是H或不同于H，Ph为苯环，在至少一个位置上用氟取代，并且至少在另一个位置上具有不同于H的取代基。
• Selective estrogen receptor modulators containing a phenylsulfonyl group
  申请人：Dally Dean Robert

  公开号：US20060183736A1

  公开（公告）日：2006-08-17

  The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

  本发明涉及式I的选择性雌激素受体调节剂或其药物酸盐加合物；例如，用于治疗子宫内膜异位症和/或子宫平滑肌瘤/平滑肌瘤。
• SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP
  申请人：Dally Robert Dean

  公开号：US20080214612A1

  公开（公告）日：2008-09-04

  The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

  本发明涉及公式I的选择性雌激素受体调节剂或其药物酸盐，例如，用于治疗子宫内膜异位症和/或子宫平滑肌瘤/肌瘤。
• METHODS OF TREATING VASCULAR DISEASES USING BROMOCRIPTINE
  申请人：VeroScience LLC

  公开号：EP3090745A1

  公开（公告）日：2016-11-09

  The present invention is directed to a method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, a pro-coagulative state, and insulin resistance (with or without treating obesity or endothelial dysfunction), associated with or independent from Metabolic Syndrome, as well as vascular disease such as cardiovascular, cerebrovascular, or peripheral vascular disease comprising the step of administering to a patient suffering from such disorders a therapeutically effective amount of a central acting dopamine agonist. In one embodiment, the central acting dopamine agonist is bromocriptine, optionally combined with a pharmaceutically acceptable carrier.

  本发明涉及一种同时治疗高血压、高甘油三酯血症、促炎症状态、促凝血状态和胰岛素抵抗（治疗或不治疗肥胖或内皮功能障碍）（与代谢综合征有关或无关）以及心血管、脑血管或外周血管疾病等血管疾病的方法，该方法包括向患有此类疾病的患者施用治疗有效量的中枢作用多巴胺激动剂。在一个实施方案中，中枢作用多巴胺激动剂是溴隐亭，可选择与药学上可接受的载体结合使用。
• METHODS OF TREATING METABOLIC SYNDROME USING DOPAMINE RECEPTOR AGONISTS
  申请人：VeroScience LLC

  公开号：EP2175853A1

  公开（公告）日：2010-04-21